Veracyte (NASDAQ: VCYT) reported Q3 EPS of ($0.02), $0.05 better than the analyst estimate of ($0.07). Revenue for the quarter ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News Earnings Guidance Management Comments

Veracyte Announces Third Quarter 2019 Financial Results and Business ProgressOctober 22, 2019 4:15 PM Veracyte (VCYT) Announces New Clinical Data Showing First-Ever Noninvasive Nasal Swab Test Can Enable Early Lung Cancer Detection and DiagnosisOctober 22, 2019 7:08 AM Veracyte (VCYT) Announces New Data Showing Envisia Genomic Classifier Improves IPF DiagnosisOctober 21, 2019 9:58 AM